Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
J Infect Public Health ; 17(6): 1050-1056, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38688178

ABSTRACT

BACKGROUND: Chikungunya virus (CHIKV) is an alphavirus (genus Alphavirus, family Togaviridae) that is primarily transmitted to humans by Aedes mosquitoes, and can be transmitted from mother to child. Little is known about CHIKV transmission in Vietnam, where dengue is endemic and Aedes mosquitoes are abundant. This study aimed to determine the prevalence and characteristics of vertical CHIKV infection in a birth cohort, and seroprevalence of anti-CHIKV antibodies with or without confirmation by neutralization tests among women bearing children in Vietnam. METHODS: We collected umbilical cord blood plasma samples from each newly delivered baby in Nha Trang, Central Vietnam, between July 2017 and September 2018. Samples were subjected to molecular assay (quantitative real-time RT-PCR) and serological tests (anti-CHIKV IgM capture and IgG indirect enzyme-linked immunosorbent assay, and neutralization tests). RESULTS: Of the 2012 tested cord blood samples from newly delivered babies, the CHIKV viral genome was detected in 6 (0.3%) samples by RT-PCR, whereas, 15 samples (0.7%) were anti-CHIKV-IgM positive. Overall, 18 (0.9%, 95% CI: 0.6-1.5) samples, including three positives for both CHIKV IgM and viral genome on RT-PCR, were regarded as vertical transmission of CHIKV infection. Of the 2012 cord blood samples, 10 (0.5%, 95% CI: 0.2-0.9) were positive for both anti-CHIKV IgM and IgG. Twenty-nine (1.4%, 95% CI: 1.0-2.1) were seropositive for anti-CHIKV IgG while 26 (1.3%, 95% CI: 0.8-1.9) of them were also positive for neutralizing antibodies, and regarded as seropositive with neutralization against CHIKV infection. CONCLUSION: This is the first report of a possible CHIKV maternal-neonatal infection in a birth cohort in Vietnam. The findings indicate that follow-up and a differential diagnosis of CHIKV infection in pregnant women are needed to clarify the potential for CHIKV vertical transmission and its impact in the newborn.


Subject(s)
Antibodies, Viral , Chikungunya Fever , Chikungunya virus , Fetal Blood , Immunoglobulin G , Immunoglobulin M , Infectious Disease Transmission, Vertical , Humans , Vietnam/epidemiology , Fetal Blood/virology , Infectious Disease Transmission, Vertical/statistics & numerical data , Female , Antibodies, Viral/blood , Chikungunya Fever/transmission , Chikungunya Fever/epidemiology , Chikungunya virus/isolation & purification , Chikungunya virus/immunology , Chikungunya virus/genetics , Immunoglobulin M/blood , Adult , Seroepidemiologic Studies , Immunoglobulin G/blood , Infant, Newborn , Pregnancy , Birth Cohort , Male , Prevalence , Young Adult , Antibodies, Neutralizing/blood , Enzyme-Linked Immunosorbent Assay , Neutralization Tests
3.
Hum Vaccin Immunother ; 17(9): 3156-3161, 2021 09 02.
Article in English | MEDLINE | ID: mdl-34081575

ABSTRACT

Following a rubella outbreak in 2011, Vietnam implemented a mass measles-rubella vaccination campaign for children aged 1-14 years in 2014-2015, further expanding the target age to 16-17 years in 2016; routine vaccination was introduced in 2014. However, there was concern that a substantial proportion of women of child-bearing age were still susceptible to rubella, with the fear of congenital rubella emergence. Thus, we conducted a prospective cohort study in Nha Trang, Vietnam, from 2017-2018 to investigate pregnant women's susceptibility to rubella infection, the incidence of congenital rubella infection, and factors associated with susceptibility. Cord blood was tested for rubella-specific immunoglobulin M (IgM) and IgG; neonatal saliva and cord blood specimens were examined for rubella-RNA. We analyzed 2013 mother-baby pairs. No baby was rubella-IgM or rubella-RNA positive. Overall, 20.4% of mothers were seronegative (95% confidence interval, 18.6%-22.1%). The seronegativity was significantly low among mothers aged <35 years. We found that maternal age groups of 20-24 and 25-29 years, and the lack of self-reported vaccination history were significantly associated with seronegativity. Many pregnant women who were not covered by the vaccination campaign are still at risk of rubella infection.


Subject(s)
Mothers , Rubella , Antibodies, Viral , Female , Humans , Incidence , Infant , Infant, Newborn , Pregnancy , Prospective Studies , Rubella/epidemiology , Rubella/prevention & control , Rubella Vaccine , Seroepidemiologic Studies , Vietnam/epidemiology
4.
Am J Trop Med Hyg ; 103(5): 2059-2064, 2020 11.
Article in English | MEDLINE | ID: mdl-32815502

ABSTRACT

To detect congenital ZIKV infection (CZI) in a birth cohort and among high-risk neonates in Vietnam, we collected umbilical cord blood plasma samples of newly delivered babies and peripheral plasma samples of high-risk neonates in Nha Trang, central Vietnam, between July 2017 and September 2018. Samples were subjected to serological and molecular tests. Of the 2013 newly delivered babies, 21 (1%) were positive for Zika virus (ZIKV) IgM and 1,599 (79%) for Flavivirus IgG. Among the 21 ZIKV IgM-positives, 11 were confirmed to have CZI because their plasma samples had anti-ZIKV neutralization titers ≥ 4 times higher than those against dengue virus (DENV)-1 to 4 and Japanese encephalitis virus (JEV) and were tested for the ZIKV RNA positive by real-time reverse transcription-PCR. Therefore, the incidence of CZI in our birth cohort was approximately 0.5%. Of the 150 high-risk neonates, three (2%) and 95 (63%) were positive for ZIKV IgM and Flavivirus IgG antibodies, respectively. None of the three ZIKV IgM-positives had ≥ 4 times higher anti-ZIKV neutralization titers than those against DENV-1 to 4 and JEV, and were therefore considered as probable CZI. Our results indicate that CZI is not rare in Vietnam. Although those with confirmed CZI did not show apparent symptoms suspected of congenital Zika syndrome at birth, detailed examinations and follow-up studies are needed to clarify the CZI impact in Vietnam. This is the first report of CZI cases in a birth cohort in Asia.


Subject(s)
Zika Virus Infection/congenital , Zika Virus Infection/epidemiology , Animals , Chlorocebus aethiops , Cohort Studies , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant, Newborn , Infectious Disease Transmission, Vertical , Male , Vero Cells , Vietnam/epidemiology
5.
Leuk Res Rep ; 11: 27-30, 2019.
Article in English | MEDLINE | ID: mdl-31049285

ABSTRACT

A 17-year-old male received allogeneic transplantation for acute lymphoblastic leukemia, and presented with generalized seizures due to a solitary brain lesion with massive necrosis on day +621. Epstein-Barr virus (EBV) DNA copies were below the cut-off value in plasma. Stereotactic biopsy of the cerebral lesion confirmed the diagnosis of post-transplant lymphoproliferative disorder (PTLD) with large atypical cells positive for CD20 and EBER. In order to diagnose primary central nervous system PTLD, the biopsy should be applied as early as possible when brain lesion with necrosis develops in post-transplant patients regardless of EBV-DNA in plasma.

9.
BMC Pediatr ; 16(1): 141, 2016 08 22.
Article in English | MEDLINE | ID: mdl-27550172

ABSTRACT

BACKGROUND: Ganciclovir is a therapeutic choice for extremely premature infants with severe postnatal cytomegalovirus disease, but little is known about its optimal dose size and dosing interval for them. CASE PRESENTATION: We treated an extremely premature female infant with postnatal cytomegalovirus infection with intravenous administration of ganciclovir since 49 days of life (postmenstrual age of 31 weeks). After ganciclovir treatment was initiated at a dose of 5 mg/kg every 12 h, cytomegalovirus loads in the peripheral blood were markedly decreased. However, since plasma ganciclovir trough level was too high, the interval was extended to every 24 h. Subsequently, the trough level and the estimated 12-h area under the concentration-time curve (AUC0-12) were decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of viremia and clinical condition. Adjustment of dosing interval from 24 h to 12 h led to a peak level of 4.2 mg/L, trough level of 1.1 mg/L, and AUC0-12 of 31.8 mg · h/L, resulting in a marked suppression of viral load. CONCLUSIONS: Monitoring the therapeutic drug levels and cytomegalovirus loads is useful in obtaining a proper treatment effect and preventing overdosage during ganciclovir therapy in premature infants with postnatal cytomegalovirus infection.


Subject(s)
Antiviral Agents/administration & dosage , Cytomegalovirus Infections/drug therapy , Drug Monitoring , Ganciclovir/administration & dosage , Infant, Extremely Low Birth Weight , Infant, Extremely Premature , Infant, Premature, Diseases/drug therapy , Antiviral Agents/therapeutic use , Area Under Curve , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Ganciclovir/therapeutic use , Humans , Infant, Newborn , Viral Load
10.
Brain Dev ; 37(2): 200-5, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24768169

ABSTRACT

AIM: Congenital cytomegalovirus (CMV) infection can cause a variety of neurological deficits of delayed onset in infants who are asymptomatic at birth. The aim of this study was to investigate the prevalence of congenital CMV infection among children with autism spectrum disorder (ASD) in Nagasaki, Japan. METHODS: Twenty-nine children with ASD who were born in Nagasaki and had no other major neurological deficits were recruited. Two of the patients were excluded due to significant perinatal events. The remaining 27 children were investigated retrospectively for congenital CMV infection by analyzing dried blood spot samples or dried umbilical cords for CMV DNA using real-time PCR. RESULTS: CMV DNA was detected in two (7.4%) of the 27 children. Neither of the patients had perinatal histories suggestive of congenital CMV disease or other neurological deficits, including hearing impairment and epilepsy. The severity of their autistic disorders varied considerably. CONCLUSIONS: The rate of congenital CMV infection in this study (two of 27 children with ASD), which was significantly (p=0.004) higher than the incidence of congenital CMV infection in Nagasaki (0.31%, 10/3230 live births), suggests the involvement of congenital CMV infection in a portion of children with ASD, although definite diagnosis was not obtained due to limited clinical data of the study subjects.


Subject(s)
Child Development Disorders, Pervasive/complications , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/diagnosis , Cytomegalovirus/genetics , Child , Child Development Disorders, Pervasive/epidemiology , Child, Preschool , Cytomegalovirus/pathogenicity , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/epidemiology , Epilepsy/etiology , Female , Hearing Loss/etiology , Humans , Infant , Male , Retrospective Studies , Severity of Illness Index
12.
Nihon Rinsho ; 70(4): 635-41, 2012 Apr.
Article in Japanese | MEDLINE | ID: mdl-22568146

ABSTRACT

Principally speaking, "drug" and "poison" are of the same class; therefore, overdose of any drug naturally leads to intoxication. Intoxication can also occur in regular doses, depending on the condition of a patient (e.g., renal insufficiency). In addition, each drug has its own side effects which occur at a certain probability, and there is no exception to antivirals. Antivirals for common acute viral diseases are used for a number of people, and those for chronic viral diseases are used for a long period. In both cases, side effects are an extremely important issue. Without precise and prompt safety measures, we won't succeed in antiviral treatment.


Subject(s)
Antiviral Agents/adverse effects , Herpesviridae/drug effects , Humans , Neuraminidase/antagonists & inhibitors , Virus Diseases/drug therapy
14.
J Pediatr ; 155(5): 749-51, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19840618

ABSTRACT

A retrospective diagnosis of congenital cytomegalovirus infection was made for 3 of 26 students (12%) with either bilateral profound or severe sensorineural hearing loss at a School for the Deaf in Japan by detecting viral DNA with real-time polymerase chain reaction from dried umbilical cords that had been preserved at home.


Subject(s)
Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/diagnosis , Cytomegalovirus/isolation & purification , Fetal Blood/virology , Hearing Loss, Sensorineural/diagnosis , Hearing Loss, Sensorineural/epidemiology , Adolescent , Child , Cytomegalovirus Infections/complications , DNA, Viral/analysis , Female , Hearing Loss, Sensorineural/etiology , Humans , Infant, Newborn , Japan/epidemiology , Male , Neonatal Screening , Persons With Hearing Impairments , Prevalence , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Risk Assessment , Students , Time Factors
15.
Acta Paediatr ; 97(12): 1686-90, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18671690

ABSTRACT

AIM: TT virus (TTV) is genetically variable and widespread without apparent pathogenicity; however, its epidemiological features in children were not fully understood, partly because blood sampling is often unacceptable for healthy children. We therefore used saliva specimens to investigate epidemiology of TTV infection in early childhood. METHODS: Saliva samples were collected from 83 1-month-old, 110 4-month-old and 49 42-month-old children. Peripheral blood mononuclear cells (PBMC) and saliva samples were obtained in pairs from 19 healthy adults aged 40 +/- 7 years. TTV DNA was detected and quantified by real-time PCR and classified into five genogroups (G1-G5) by a series of PCRs using genogroup-specific primer pairs. RESULTS: TTV DNA was detected in 6, 34 and 90% of children aged 1, 4 and 42 months, respectively, and in 84% of adults. Comparable levels of TTV DNA were detected in pairs of saliva and PBMC. TTV loads in saliva were much higher in children than in adults. G3 was the most common genogroup in all age groups. The second most prevalent was G4 at 1-4 months of age and G1 thereafter. CONCLUSION: The prevalence of TTV infection reached a plateau at or before 42 months; however, somehow different epidemiologic features were observed among genogroups.


Subject(s)
DNA Virus Infections/virology , Saliva/virology , Torque teno virus/isolation & purification , Adult , Age Factors , Child, Preschool , DNA Virus Infections/blood , DNA Virus Infections/epidemiology , DNA Virus Infections/genetics , Female , Genetic Variation , Genotype , Humans , Infant , Japan , Male , Middle Aged , Prevalence , Torque teno virus/genetics , Viral Load
16.
J Med Virol ; 80(8): 1447-51, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18551605

ABSTRACT

Mouse mammary tumor virus (MMTV) is the causative agent of breast tumors in mice. Recently, DNA sequences homologous or closely related to MMTV env gene have been specifically detected in breast cancer tissue from significant numbers of American, Australian, and Tunisian women, suggesting a viral etiology for at least a part of human breast cancer. However, the viral sequences have not been detected from any of breast cancer samples in several subsequent studies. Thus, whether MMTV-related retrovirus is a causative agent of human breast cancer remains controversial. To demonstrate if MMTV-related retrovirus is involved in Japanese cases of breast cancer, breast tissue specimens from 46 breast cancer patients and 3 patients with benign mammary tumors were investigated. Extensive analysis using PCR and Southern blot hybridization, however, could not detect the MMTV env gene-like sequence in any of the samples tested as well as in MCF7 cells that has previously been described as a positive control. Thus, MMTV itself or MMTV-related retrovirus is not associated with breast carcinogenesis in Japanese women, and it is unclear whether this conclusion is merely a reflection of regional differences in its epidemics.


Subject(s)
Breast Neoplasms , Gene Products, env/genetics , Genes, env , Mammary Tumor Virus, Mouse/isolation & purification , Adenocarcinoma, Mucinous/epidemiology , Adenocarcinoma, Mucinous/genetics , Adenocarcinoma, Mucinous/virology , Adult , Aged , Aged, 80 and over , Animals , Blotting, Southern , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Breast Neoplasms/virology , Carcinoma, Ductal, Breast/epidemiology , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/virology , Carcinoma, Intraductal, Noninfiltrating/epidemiology , Carcinoma, Intraductal, Noninfiltrating/genetics , Carcinoma, Intraductal, Noninfiltrating/virology , Cell Line, Tumor , Female , Fibroadenoma/epidemiology , Fibroadenoma/genetics , Fibroadenoma/virology , Humans , Japan/epidemiology , Mammary Tumor Virus, Mouse/genetics , Mice , Middle Aged , Nucleic Acid Hybridization , Phyllodes Tumor/epidemiology , Phyllodes Tumor/genetics , Phyllodes Tumor/virology , Polymerase Chain Reaction
17.
Liver Transpl ; 14(5): 647-50, 2008 May.
Article in English | MEDLINE | ID: mdl-18433046

ABSTRACT

This report describes a patient who developed human T-cell leukemia virus type I-associated myelopathy (HAM) following a living-donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T-cell leukemia virus type I (HTLV-I) carriers. Since the LDLT, he had been treated with immunosuppressive drugs such as tacrolimus and steroids as well as interferon-alpha to prevent rejection and a recurrence of the HCV infection, respectively. Even though the HTLV-I proviral load had decreased upon interferon treatment, he developed a slowly progressive gait disturbance with urinary disturbance 2 years after the LDLT and was diagnosed with HAM. This appears to be the first report of HAM development in an HLTV-I-infected LDLT recipient.


Subject(s)
Hepatitis C/complications , Liver Cirrhosis/surgery , Liver Transplantation/adverse effects , Living Donors , Paraparesis, Tropical Spastic/etiology , Antiviral Agents/therapeutic use , Drug Therapy, Combination , Gait Disorders, Neurologic/etiology , Graft Rejection/prevention & control , Hepatitis C/surgery , Humans , Immunosuppressive Agents/therapeutic use , Interferon alpha-2 , Interferon-alpha/therapeutic use , Liver Cirrhosis/virology , Male , Middle Aged , Paraparesis, Tropical Spastic/complications , Paraparesis, Tropical Spastic/drug therapy , Recombinant Proteins , Steroids/therapeutic use , Tacrolimus/therapeutic use , Treatment Outcome , Urination Disorders/etiology
20.
Neonatology ; 92(4): 236-9, 2007.
Article in English | MEDLINE | ID: mdl-17570943

ABSTRACT

Several studies have reported that postnatally acquired cytomegalovirus (CMV) infection can cause sepsis-like syndrome in premature infants. We here report a 622-gram birth weight male infant of 23 weeks' gestation who had sepsis-like syndrome and pneumonia. Substantial CMV loads were detected in peripheral blood cells, plasma, and urine when the patient was in crisis, but was decreased in parallel to clinical improvement without using ganciclovir. CMV DNA was not detected from his umbilical cord or Guthrie card, even by highly sensitive real-time PCR. Molecular profiles were indistinguishable between the CMV strain isolated from his urine and that from maternal breast milk, indicating postnatal acquisition of CMV through breast milk. Although he had transient hearing impairment, his neurodevelopmental outcome of 30 months of corrected age was normal. Further accumulation of clinical and virological data in postnatal CMV infection is necessary for evaluating the severity and selecting patients requiring antiviral therapy.


Subject(s)
Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/transmission , Infant, Premature , Milk, Human/virology , Antiviral Agents/therapeutic use , Cytomegalovirus/isolation & purification , Cytomegalovirus/pathogenicity , Cytomegalovirus Infections/drug therapy , Female , Ganciclovir/therapeutic use , Humans , Infant, Newborn , Male , Pregnancy , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...